Literature DB >> 10678874

Effectiveness of rivastigmine in Alzheimer's disease. Participation in trials should be based on clinical uncertainty, not enforcement.

R Bullock, P Passmore, D Wilkinson, R Howard, R Jones.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10678874      PMCID: PMC1127540     

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  6 in total

1.  Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished.

Authors:  P Bentham; R Gray; E Sellwood; J Raftery
Journal:  BMJ       Date:  1999-09-04

Review 2.  New drug treatment for Alzheimer's disease: lessons for healthcare policy.

Authors:  D Melzer
Journal:  BMJ       Date:  1998-03-07

3.  Assessing patient dependence in Alzheimer's disease.

Authors:  Y Stern; S M Albert; M Sano; M Richards; L Miller; M Folstein; M Albert; F W Bylsma; G Lafleche
Journal:  J Gerontol       Date:  1994-09

4.  Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale.

Authors:  R S Bucks; D L Ashworth; G K Wilcock; K Siegfried
Journal:  Age Ageing       Date:  1996-03       Impact factor: 10.668

5.  The sensitivity to change over time of the Bristol Activities of Daily Living Scale in Alzheimer's disease.

Authors:  L M Byrne; P M Wilson; R S Bucks; A O Hughes; G K Wilcock
Journal:  Int J Geriatr Psychiatry       Date:  2000-07       Impact factor: 3.485

6.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years.

Authors:  D Galasko; S D Edland; J C Morris; C Clark; R Mohs; E Koss
Journal:  Neurology       Date:  1995-08       Impact factor: 9.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.